Media Articles Related to Amerge (Naratriptan)
Older Smokers With Migraines May Face Added Stroke Risk
Source: MedicineNet Headache Specialty [2015.07.31]
Title: Older Smokers With Migraines May Face Added Stroke Risk
Category: Health News
Created: 7/30/2015 12:00:00 AM
Last Editorial Review: 7/31/2015 12:00:00 AM
Migraine Ups Stroke Risk, but Only in Smokers
Source: Medscape NeurologyHeadlines [2015.07.30]
Cohort study findings contradict previous studies demonstrating an overall association between migraine with aura and vascular outcomes.
Medscape Medical News
Can migraine increase your risk of stroke?
Source: Headache / Migraine News From Medical News Today [2015.07.23]
New research suggests older people who experience migraines may have an increased risk of stroke, but only if they are smokers.
Childhood Trauma Tied to Migraine Risk as Adult
Source: MedicineNet Headache Specialty [2015.07.06]
Title: Childhood Trauma Tied to Migraine Risk as Adult
Category: Health News
Created: 7/3/2015 12:00:00 AM
Last Editorial Review: 7/6/2015 12:00:00 AM
Genes may not be to blame for link between migraine and heart disease
Source: Headache / Migraine News From Medical News Today [2015.07.03]
A new study suggests that genes may not be to blame for the increased risk of heart disease some studies have shown in people with migraine, especially those with migraine with aura.
Published Studies Related to Amerge (Naratriptan)
Published and not fully published double-blind, randomised, controlled trials
with oral naratriptan in the treatment of migraine: a review based on the GSK
Trial Register. 
Naratriptan 2.5 mg is now an over-the-counter drug in Germany.Naratriptan, when available OTC is a reasonable second or third
choice on the step care ladder in the acute treatment of migraine.
Efficacy of oral naratriptan in the treatment of menstrually related migraine. [2005.10]
The aim of this study was to investigate the efficacy of orally administered 2.5 mg naratriptan in the treatment of menstrually related migraine (MRM). A high percentage of women suffering from migraine report increased frequency of attacks in association with menstruation that may be more severe, of longer duration and more difficult to treat than at other times...
Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. [2003.11]
This was a randomized, double-blind study designed to evaluate the comparative efficacy and tolerability of the 40-mg dose of eletriptan and the 2.5-mg dose of naratriptan. Patients (n = 548) meeting International Headache Society (IHS) criteria for migraine were randomized to treat a single migraine attack with either eletriptan 40 mg, naratriptan 2.5 mg, or placebo.
Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. [2003.09]
OBJECTIVE: To evaluate the effect of acute treatment on ictal behavioral functioning of patients with migraine via ambulatory accelerometry. BACKGROUND: The inability to carry out daily activities often complicates migraine attacks. Research into the effects of pharmacological drugs on this outcome parameter in the acute treatment of migraine has been based on subjective reports only... CONCLUSIONS: Consciously perceived clinical and subjective symptoms do not necessarily run in parallel with their behavioral equivalents. It, thus, may be important to assess the effects of treatment on behavioral functioning in the evaluation of the general efficacy of antimigraine drugs in the acute treatment of a migraine attack.
Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. [2001.03]
OBJECTIVE: To determine the efficacy of naratriptan 1-mg and 2.5-mg tablets twice daily compared with placebo as short-term prophylaxis of menstrually associated migraine. BACKGROUND: Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open-label study suggest that short-term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine... CONCLUSIONS: Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short-term, prophylactic treatment for menstrually associated migraine.
Clinical Trials Related to Amerge (Naratriptan)
Sumatriptan and Naratriptan Pregnancy Registry [Recruiting]
Anti-migraine drugs, including triptans, are not indicated for use in pregnancy. However,
the peak prevalence of migraine is in women of childbearing age. This, coupled with the
sporadic nature of migraine attacks and high rates of unplanned pregnancies, makes
unintentional exposure to anti-migraine medications during pregnancy likely. Prior to an
anti-migraine medication being marketed there are few data available on drug safety in
pregnancy: data from animal models may not translate directly to humans and pregnant women
are routinely excluded from clinical trials. The Sumatriptan Pregnancy Registry was
established by GlaxoSmithKline (GSK) in 1996 to monitor the safety of sumatriptan during
pregnancy. It was combined with the Naratriptan Pregnancy Registry in 2001 and data
collection on the sumatriptan-naproxen combination (Treximet) began in 2008.
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction [Recruiting]
The purpose of this study is to determine whether naratriptan, a medication approved for
treatment of migraine, is effective in the treatment of post traumatic headache associated
with cognitive dysfunction.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine. [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan
2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute
treatment of migraine.
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine [Not yet recruiting]
The purpose of this study is to determine whether a fixed-dose combination of naratriptan +
naproxen is effective compared each monotherapy for the acute treatment of migraine.
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order [Recruiting]
In a double blind randomized clinical trial with cross-over design, treatment using
naratriptan will be compared to placebo within a group of 30 convicts with psychiatric
disorders such as psychosis or psychopathy with repeated aggressive outbursts resistant to
conventional psychopharmacologic and other psychotherapeutic treatment. Hypothesis is that
addition of naratriptan to the individual treatment regime reduces aggression - and improves
general outcome- as compared to addition of placebo and is well tolerated in this group and
under these conditions.
Reports of Suspected Amerge (Naratriptan) Side Effects
Drug Ineffective (4),
Chest Pain (4),
Stress Cardiomyopathy (4),
Troponin T Increased (3),
Eye Pain (3),
Brain Natriuretic Peptide Increased (3),
Vasospasm (3), more >>